p53 protein overexpression in early stage endometrial cancer

Gynecologic Oncology

Volumn 62, Issue 2, 1996, Pages 213-217

  Kohlberger, Petra ^a   Gitsch, Gerald ^a   Loesch, Alexander ^a   Tempfer, Clemens ^a   Kaider, Alexandra ^b   Reinthaller, Alexander ^a   Kainz, Christian ^a   Breitenecker, Gerhard ^b  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b UNIVERSITY OF VIENNA   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN P53;

ABDOMINAL HYSTERECTOMY; ADULT; AGED; ARTICLE; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; CLINICAL FEATURE; EARLY CANCER; ENDOMETRIUM CANCER; FEMALE; FOLLOW UP; HISTOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPHADENECTOMY; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; SALPINGOOOPHORECTOMY;

EID: 0030220756     PISSN: 00908258     EISSN: None     Source Type: Journal    
DOI: 10.1006/gyno.1996.0218     Document Type: Article

References (39)

1. 1. Hainaut, P. The tumor suppressor protein p53: A receptor to genotoxic stress that controls cell growth and survival, Curr. Opin. Oncol. 7, 76-82 (1995).
2. 2. Finlay, C. A., Hinds, P. W., and Levine, A. J. The p53 oncogene can act as a suppressor of transformation, Cell 57, 1083-1093 (1989).
3. 3. Mercer, W. E., Acignolo, C., and Berserga, R. Role of the p53 protein in cell proliferation as studied by microinjection of monoclonal antibodies, Mol. Cell. Biol. 4, 276-282 (1984).
4. 4. Levine, A. J., Momand, J., and Finlay, K. A. The p53 tumour suppressor gene, Nature 351, 453-456 (1991).
5. 5. Mack, T. M., Cozen, W., and Quinn, M. A. Epidemiology of cancer of the endometrium, ovary, vulva and vagina, in Gynecologic oncology (M. Coppleson, Ed.), Chruchill Livingstone, Edinburgh, pp. 31-54 (1992).
6. 6. Hacker, N. F. Uterine cancer, in Practical gynecologic oncology (J. S. Berek and N. F. Hacker, Eds.), Williams & Wilkins, Baltimore, pp. 285-314 (1994).
7. 7. Morrow, C. P., Bundy, B. N., Kurmann, R. J., Creasman, W. T., Heller, P., Homesley, H. D., and Graham, J. E. Relationship between surgical-pathological risk factors and outcome in clinical stage I and II carcinoma of the endometrium: A Gynecologic Oncology Group study, Gynecol. Oncol. 40, 55-65 (1991).
8. 8. FIGO stages: 1988 revision. Gynecol. Oncol. 35, 125-127 (1989).
9. 9. Ito, K., Watanabe, K., Nasim, S., Sasano, H., Sato, S., Yajima, A., Silverberg, S. G., and Garrett, C. T. Prognostic significance of p53 overexpression in endometrial cancer, Cancer Res. 54, 4667-4670 (1994).
10. 10. Inoue, M., Okayama, A., Fujita, M., Enomoto, T., Sakata, M., Tanizawa, O., and Ueshima, H. Clinicopathological characteristics of p53 overexpression in endometrial cancers, Int. J. Cancer 58, 14-19 (1994).
11. 11. Lukes, A. S., Kohler, M. F., Pieper, C. F., Kerns, B. J., Bentley, R., Rodriguez, G. C., Soper, J. T., Clarke-Pearson, D. L., Bast, R. C., and Berchuck, A. Multivariable analysis of DNA ploidy, p53, and HER-2/neu as prognostic factors in endometrial cancer, Cancer 73, 2380-2385 (1994).
12. 12. Nielsen, A. L., and Nyholm, H. C. J. p53 and c-erbB-2 protein (p185) expression in endometrial adenocarcinoma of endometrioid type. An immunohistochemical examination on paraffin sections, Am. J. Clin. Pathol. 102, 76-79 (1994).
13. 13. Pisani, A. L., Barbuto, D. A., Chen, D., Ramos, L., Lagasse, L. D., and Karlan, B. Y. HER-2/neu, p53, and DNA analyses as prognosticators for survival in endometrial carcinoma, Obstet. Gynecol. 85, 729-734 (1995).
14. 14. Inoue, M., Fujita, M., Enomoto, T., Morimoto, H., Monden, T., Shimano, T., and Tanizawa, O. Immunohistochemical analysis of p53 in gynecologic tumors, Am. J. Clin. Pathol. 102, 665-670 (1994).
15. 15. Kohler, M. F., Berchuck, A., Davidoff, A. M., Humhrey, P. A., Dodge, R. K., Iglehart, J. D., Soper, J. T., Clarke-Pearson, D. L., Bast, R. C., and Marks, J. R. Overexpression and mutation of p53 in endometrial carcinoma, Cancer Res. 52, 1622-1627 (1992).
16. 16. Bur, M. E., Perlman, C., Edelmann, L., Fey, E., and Rose, P. G. p53 expression in neoplasms of the uterine corpus, Am. J. Clin. Pathol. 98, 81-87 (1992).
17. 17. Reinartz, J. J., George, E., Lindgren, B. R., and Niehans, G. A. Expression of p53, transforming growth factor alpha, epidermal growth factor receptor, and c-erbB-2 in endometrial carcinoma and correlation with survival and known predictors of survival, Hum. Pathol. 25, 1075-1083 (1994).
18. 18. Khalifa, M. A., Mannel, R. S., Haraway, S. D., Walker, J., and Min, K.-W. Expression of EGFR, HER-2/neu, P53, and PCNA in endometrioid, serous papillary, and clear cell endometrial adenocarcinomas, Gynecol. Oncol. 53, 84-92 (1994).
19. 19. Kohler, M. F., Nishii, H., Humphrey, P. A., Saski, H., Marks, J., Bast, R. C., Clarke-Pearson, D. L., Boyd, J., and Berchuck, A. Mutation of the p53 tumor-suppressor gene is not a feature of endometrial hyperplasias, Am. J. Obstet. Gynecol. 169, 690-694 (1993).
20. 20. Ambros, R. A., Vigna, P. A., Figge, J., Kallakury, B. V. S., Mastrangelo, A., Eastman, A. Y., Malfetano, J., Figge, H. L., and Ross, J. S. Observations on tumor and metastatic suppressor gene status in endometrial carcinoma with particular emphasis on p53, Cancer 73, 1686-1692 (1994).
21. 21. Berchuck, A., Kohler, M. F., Marks, J. R., Wiseman, R., Boyd, J., and Bast, R. C., Jr. The p53 tumor suppressor gene frequently is altered in gynecologic cancers, Am. J. Obstet. Gynecol. 170, 246-252 (1994).
22. 22. Yu, C. C., Wilkinson, N., Brito, M. J., Buckley, C. H., Fox, H., and Levison, D. A. Patterns of immunohistochemical staining for proliferating cell nuclear antigen and p53 in benign and neoplastic human endometrium, Histopathology 23, 367-371 (1993).
23. 23. Koshiyama, M., Konishi, I., Wang, D. P., Mandai, M., Komatsu, T., Yamamoto, S., Nanbu, K., Naito, M. F., and Mori, T. Immunohistochemical analysis of p53 protein over-expression in endometrial carcinomas: Inverse correlation with sex steroid receptor status, Virchows Arch. A Pathol. Anat. Histopathol. 423, 265-271 (1993).
24. 24. Ambros, R. A., Ross, J. S., Kallakury, B. V., Malfetano, J., Kim, Y., Hwang, J., Breese, K., and Figge, J. p53 gene status in endometrial carcinomas showing diffuse positivity for p53 protein by immunohistochemical analysis, Mod. Pathol. 8, 441-445 (1995).
25. 25. King, S. A., Adas, A. A., LiVolsi, V. A., Takahashi, H., Behbakht, K., McGovern, P., Benjamin, I., Rubin, S. C., and Boyd, J. Expression and mutation analysis of the p53 gene in uterine papillary serous carcinoma, Cancer 75, 2700-2705 (1995).
26. 26. Malviya, V. K., Deppe, G., Malone, J. M., Jr., Sundareson, A. S., and Lawrence, W. D. Reliability of frozen section examination in identifying poor prognostic indicators in stage I endometrial adenocarcinoma, Gynecol. Oncol. 34, 299-304 (1989).
27. 27. Hermanek, P., and Sobin, L. H., Eds. UICC TNM classification of malignant tumours, 4th ed., 2nd rev., Springer-Verlag, Berlin (1992).
28. 28. Kohlberger, P., Kainz, C., Breitenecker, G., Gitsch, G., Sliutz, G., Kölbl, H., Tschachler, E., and Reinthaller, A. Prognostic value of immunohistochemically detected p53 expression in vulvar carcinoma, Cancer 76, 1786-1789 (1995).
29. 29. Kaplan, E. L., and Meier, P. Nonparametric estimation from incomplete observations, J. Am. Stat. Assoc. 53, 457-481 (1958).
30. 30. Cox, D. R. Regression models and life-tables (with discussion), J. R. Stat. Soc. Ser. B 34, 187-220 (1972).
31. 31. Oka, K., Nakano, T., and Arai, T. p53CM1 expression is not associated with prognosis in uterine cervical carcinoma, Cancer 72, 160-164 (1993).
32. 32. Gannon, J. V., Greaves, R., Iggo, R., and Lane, D. P. Activating mutations in p53 produce a common conformational effect. A monoclonal antibody specific for the mutant form, EMBO J. 9, 1595-1602 (1990).
33. 33. Battifora, H. p53 immunohistochemistry: A word of caution, Hum. Pathol. 25, 435-437 (1994).
34. 34. Marks, J. R., Davidoff, A. M., Kerns, B. J., Humphrey, P. A., Pence, J. C., Doudge, R. K., Clarke-Pearson, D. L., Bast, R. C., and Berchuck, A. Overexpression and mutation of p53 in epithelial ovarian cancer, Cancer Res. 51, 2979-2984 (1991).
35. 35. Schneider, J., Rubio, M. P., Rodriguez-Escudero, F. J., Seizinger, B. R., and Castresana, J. S. Identification of p53 mutations by means of single strand conformation polymorphism analysis in gynaecological tumours: Comparison with the results of immunohistochemistry, Eur. J. Cancer 30A, 504-508 (1994).
36. 36. Cordon-Cardo, C., Dalbagni, G., Saez, G. T., Oliva, M. R., Zhang, Z. F., Rosai, J., Reuter, V. E., and Pellicer, A. p53 mutations in human bladder cancer: Genotypic versus phenotypic patterns, Int. J. Cancer 56, 347-353 (1994).
37. 37. Hachisuga, T., Fukuda, K., Uchiyama, M., Matsuo, N., Iwasaka, T., and Sugimori, H. Immunohistochemical study of p53 expression in endometrial carcinomas: Correlation with markers of proliferating cells and clinicopathologic features, Int. J. Gynecol. Cancer 3, 363-368 (1993).
38. 38. Miller, B., Umpierre, S., Tornos, C., and Burke, T. Histologic characterization of uterine papillary serous adenocarcinoma, Gynecol. Oncol. 56, 425-429 (1995).
39. 39. Prat, J., Oliva, E., Lerma, E., Vaquero, M., and Matias-Guiu, X. Uterine papillary serous adenocarcinoma, Cancer 74, 1778-1783 (1994).